Chemistry:NS-2359
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C15H19Cl2NO |
| Molar mass | 300.22 g·mol−1 |
| 3D model (JSmol) | |
| |
| (verify) | |
NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials showed the drug was not effective and not well tolerated.[2] The results did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatment of ADHD,[3] phase II having been completed in 2007.[4] A phase I clinical trial exploring the effect of NS-2359 on cocaine-dependent individuals was completed in 2002.[5]
See also
References
- ↑ 1.0 1.1 "NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression". NeuroSearch. https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=313018&messageId=372903.
- ↑ "Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials". Journal of Psychopharmacology 26 (5): 653–62. May 2012. doi:10.1177/0269881111424931. PMID 22048884.
- ↑ "A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD". Behavioral and Brain Functions 4: 24. June 2008. doi:10.1186/1744-9081-4-24. PMID 18554401.
- ↑ Clinical trial number NCT00467428 for "Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder" at ClinicalTrials.gov
- ↑ Clinical trial number NCT00032916 for "Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers" at ClinicalTrials.gov
 |  |
